Abacavir and Lamivudine tablets

Product Description

The combination of Abacavir and Lamivudine is a commonly prescribed antiretroviral medication used in the treatment of HIV (human immunodeficiency virus) infection. This combination is often provided in a fixed-dose tablet to simplify the treatment regimen for individuals living with HIV.

Here are some key points about Abacavir and Lamivudine tablets:

1. Abacavir:

   • Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI).
   • It inhibits the reverse transcriptase enzyme, disrupting the replication of the HIV virus.
   • Abacavir is often used in combination with other antiretroviral drugs as part of a comprehensive HIV treatment plan.

2. Lamivudine:

   • Lamivudine is also a nucleoside reverse transcriptase inhibitor (NRTI).
   • It inhibits the reverse transcriptase enzyme, preventing the replication of the HIV virus.
   • Like Abacavir, Lamivudine is commonly used in combination therapy for HIV.

Key points about Abacavir and Lamivudine tablets:

• Indications: This combination is used for the treatment of HIV-1 infection in adults and pediatric patients.

• Dosage: The typical dosage involves taking one tablet orally once or twice daily, as prescribed by a healthcare professional. The specific dosage may vary based on the individual's health condition and overall HIV treatment plan.

• Adherence: Adherence to the prescribed regimen is crucial for the effectiveness of HIV treatment. Missing doses or not taking the medication as directed can lead to reduced efficacy and the development of drug resistance.

• Hypersensitivity: Before starting this medication, individuals are typically screened for the HLA-B*5701 allele, as individuals carrying this allele have an increased risk of a severe hypersensitivity reaction to abacavir.

• Side Effects: Potential side effects may include nausea, headache, and fatigue. It's important to report any severe or persistent side effects to a healthcare provider.

• Pregnancy: The use of this combination during pregnancy should be discussed with a healthcare provider, taking into consideration the potential risks and benefits.

Individuals prescribed with Abacavir and Lamivudine tablets should follow the guidance of their healthcare provider, undergo regular monitoring, and communicate any concerns or side effects experienced during the treatment. As always, individual circumstances may vary, and healthcare providers can provide personalized information based on the patient's medical history and needs

Convenient Fixed-Dose Combination

Abacavir and Lamivudine tablets offer the advantage of once-daily dosing, making HIV management more straightforward and improving adherence to therapy. By combining two effective nucleoside reverse transcriptase inhibitors in a single tablet, the regimen simplifies treatment and supports consistent viral suppression in adults and adolescents.


Stringent Safety Measures and Monitoring

Before starting Abacavir and Lamivudine, it is crucial to screen for the HLA-B*5701 allele to minimize the risk of hypersensitivity. Patients must be monitored regularly for signs of hypersensitivity and lactic acidosis. Contraindicated in individuals allergic to either active ingredient, these precautions underscore the commitment to patient safety.